Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of ZYPREXA and ZYPREXA VELOTAB in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ZYPREXA and ZYPREXA VELOTAB, as with all other anti-psychotics (including first generation anti-psychotics), provide a moderate Improvement in Actual Benefit (IAB III) in the treatment of schizophrenia. |
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
ggHGUHm6zXubhqj1
